vs
Side-by-side financial comparison of Elanco Animal Health Inc (ELAN) and UGI CORP (UGI). Click either name above to swap in a different company.
UGI CORP is the larger business by last-quarter revenue ($2.1B vs $1.1B, roughly 1.8× Elanco Animal Health Inc). UGI CORP runs the higher net margin — 14.4% vs -24.1%, a 38.5% gap on every dollar of revenue. On growth, Elanco Animal Health Inc posted the faster year-over-year revenue change (12.2% vs 3.9%). Elanco Animal Health Inc produced more free cash flow last quarter ($46.0M vs $-155.0M). Over the past eight quarters, Elanco Animal Health Inc's revenue compounded faster (-2.6% CAGR vs -7.5%).
Elanco Animal Health Incorporated is an American pharmaceutical company which produces medicines and vaccinations for pets and livestock. Until 2019, the company was a subsidiary of Eli Lilly and Company, before being divested. It is the third-largest animal health company in the world.
UGI Corporation is a natural gas and electric power distribution company headquartered in King of Prussia, Pennsylvania, with extensive operations in the United States and Europe.
ELAN vs UGI — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.1B | $2.1B |
| Net Profit | $-276.0M | $297.0M |
| Gross Margin | 51.5% | — |
| Operating Margin | -22.6% | 22.0% |
| Net Margin | -24.1% | 14.4% |
| Revenue YoY | 12.2% | 3.9% |
| Net Profit YoY | -3350.0% | -20.8% |
| EPS (diluted) | $-0.55 | $1.34 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.1B | $2.1B | ||
| Q3 25 | $1.1B | $1.2B | ||
| Q2 25 | $1.2B | $1.4B | ||
| Q1 25 | $1.2B | $2.6B | ||
| Q4 24 | $1.0B | $2.0B | ||
| Q3 24 | $1.0B | $1.2B | ||
| Q2 24 | $1.2B | $1.4B | ||
| Q1 24 | $1.2B | $2.4B |
| Q4 25 | $-276.0M | $297.0M | ||
| Q3 25 | $-34.0M | $-13.0M | ||
| Q2 25 | $11.0M | $-163.0M | ||
| Q1 25 | $67.0M | $479.0M | ||
| Q4 24 | $-8.0M | $375.0M | ||
| Q3 24 | $364.0M | $-273.0M | ||
| Q2 24 | $-50.0M | $-48.0M | ||
| Q1 24 | $32.0M | $496.0M |
| Q4 25 | 51.5% | — | ||
| Q3 25 | 53.4% | — | ||
| Q2 25 | 57.5% | — | ||
| Q1 25 | 57.3% | — | ||
| Q4 24 | 50.9% | — | ||
| Q3 24 | 52.2% | — | ||
| Q2 24 | 58.2% | — | ||
| Q1 24 | 57.3% | — |
| Q4 25 | -22.6% | 22.0% | ||
| Q3 25 | -4.4% | 1.1% | ||
| Q2 25 | 2.0% | -6.8% | ||
| Q1 25 | 5.0% | 26.6% | ||
| Q4 24 | -5.0% | 24.5% | ||
| Q3 24 | 54.3% | -20.4% | ||
| Q2 24 | -2.7% | 5.0% | ||
| Q1 24 | 1.0% | 29.7% |
| Q4 25 | -24.1% | 14.4% | ||
| Q3 25 | -3.0% | -1.1% | ||
| Q2 25 | 0.9% | -12.0% | ||
| Q1 25 | 5.6% | 18.2% | ||
| Q4 24 | -0.8% | 18.9% | ||
| Q3 24 | 35.3% | -22.6% | ||
| Q2 24 | -4.2% | -3.6% | ||
| Q1 24 | 2.7% | 20.6% |
| Q4 25 | $-0.55 | $1.34 | ||
| Q3 25 | $-0.07 | $-0.08 | ||
| Q2 25 | $0.02 | $-0.76 | ||
| Q1 25 | $0.13 | $2.19 | ||
| Q4 24 | $-0.01 | $1.74 | ||
| Q3 24 | $0.73 | $-1.26 | ||
| Q2 24 | $-0.10 | $-0.23 | ||
| Q1 24 | $0.06 | $2.30 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $545.0M | $251.0M |
| Total DebtLower is stronger | $3.9B | $6.0B |
| Stockholders' EquityBook value | $6.5B | $5.0B |
| Total Assets | $13.4B | $15.8B |
| Debt / EquityLower = less leverage | 0.60× | 1.19× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $545.0M | $251.0M | ||
| Q3 25 | $505.0M | $335.0M | ||
| Q2 25 | $539.0M | $350.0M | ||
| Q1 25 | $487.0M | $426.0M | ||
| Q4 24 | $468.0M | $240.0M | ||
| Q3 24 | $490.0M | $213.0M | ||
| Q2 24 | $416.0M | $183.0M | ||
| Q1 24 | $345.0M | $263.0M |
| Q4 25 | $3.9B | $6.0B | ||
| Q3 25 | $4.0B | $6.5B | ||
| Q2 25 | $4.1B | $5.7B | ||
| Q1 25 | $4.4B | $6.6B | ||
| Q4 24 | $4.3B | $6.6B | ||
| Q3 24 | $4.4B | $6.4B | ||
| Q2 24 | $5.7B | $6.3B | ||
| Q1 24 | $5.8B | $6.7B |
| Q4 25 | $6.5B | $5.0B | ||
| Q3 25 | $6.7B | $4.8B | ||
| Q2 25 | $6.8B | $4.9B | ||
| Q1 25 | $6.4B | $5.0B | ||
| Q4 24 | $6.1B | $4.6B | ||
| Q3 24 | $6.5B | $4.3B | ||
| Q2 24 | $5.9B | $4.7B | ||
| Q1 24 | $6.1B | $4.8B |
| Q4 25 | $13.4B | $15.8B | ||
| Q3 25 | $13.6B | $15.5B | ||
| Q2 25 | $13.7B | $15.4B | ||
| Q1 25 | $12.9B | $15.7B | ||
| Q4 24 | $12.6B | $15.4B | ||
| Q3 24 | $13.3B | $15.1B | ||
| Q2 24 | $13.8B | $15.1B | ||
| Q1 24 | $14.0B | $15.6B |
| Q4 25 | 0.60× | 1.19× | ||
| Q3 25 | 0.59× | 1.37× | ||
| Q2 25 | 0.61× | 1.17× | ||
| Q1 25 | 0.69× | 1.32× | ||
| Q4 24 | 0.70× | 1.44× | ||
| Q3 24 | 0.67× | 1.48× | ||
| Q2 24 | 0.96× | 1.34× | ||
| Q1 24 | 0.95× | 1.40× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $108.0M | $66.0M |
| Free Cash FlowOCF − Capex | $46.0M | $-155.0M |
| FCF MarginFCF / Revenue | 4.0% | -7.5% |
| Capex IntensityCapex / Revenue | 5.4% | 10.7% |
| Cash ConversionOCF / Net Profit | — | 0.22× |
| TTM Free Cash FlowTrailing 4 quarters | $284.0M | $282.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $108.0M | $66.0M | ||
| Q3 25 | $219.0M | $90.0M | ||
| Q2 25 | $237.0M | $289.0M | ||
| Q1 25 | $-4.0M | $684.0M | ||
| Q4 24 | $177.0M | $164.0M | ||
| Q3 24 | $162.0M | $151.0M | ||
| Q2 24 | $200.0M | $390.0M | ||
| Q1 24 | $2.0M | $522.0M |
| Q4 25 | $46.0M | $-155.0M | ||
| Q3 25 | $127.0M | $-168.0M | ||
| Q2 25 | $180.0M | $67.0M | ||
| Q1 25 | $-69.0M | $538.0M | ||
| Q4 24 | $130.0M | $-47.0M | ||
| Q3 24 | $120.0M | $-115.0M | ||
| Q2 24 | $166.0M | $185.0M | ||
| Q1 24 | $-22.0M | $353.0M |
| Q4 25 | 4.0% | -7.5% | ||
| Q3 25 | 11.2% | -14.4% | ||
| Q2 25 | 14.5% | 4.9% | ||
| Q1 25 | -5.8% | 20.4% | ||
| Q4 24 | 12.7% | -2.4% | ||
| Q3 24 | 11.7% | -9.5% | ||
| Q2 24 | 14.0% | 13.7% | ||
| Q1 24 | -1.8% | 14.6% |
| Q4 25 | 5.4% | 10.7% | ||
| Q3 25 | 8.1% | 22.1% | ||
| Q2 25 | 4.6% | 16.3% | ||
| Q1 25 | 5.4% | 5.5% | ||
| Q4 24 | 4.6% | 10.6% | ||
| Q3 24 | 4.1% | 22.0% | ||
| Q2 24 | 2.9% | 15.2% | ||
| Q1 24 | 2.0% | 7.0% |
| Q4 25 | — | 0.22× | ||
| Q3 25 | — | — | ||
| Q2 25 | 21.55× | — | ||
| Q1 25 | -0.06× | 1.43× | ||
| Q4 24 | — | 0.44× | ||
| Q3 24 | 0.45× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.06× | 1.05× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ELAN
| Pet Health | $489.0M | 43% |
| Cattle | $296.0M | 26% |
| Poultry | $237.0M | 21% |
| Swine | $107.0M | 9% |
| Contract Manufacturing | $15.0M | 1% |
UGI
Segment breakdown not available.
